Pulmonary function following hyperbaric oxygen therapy: A longitudinal observational study
Hyperbaric oxygen therapy (HBOT) is known to be associated with pulmonary oxygen toxicity. However, the effect of modern HBOT protocols on pulmonary function is not completely understood. The present study evaluates pulmonary function test changes in patients undergoing serial HBOT. We prospectively...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231819/?tool=EBI |
| _version_ | 1797812011019534336 |
|---|---|
| author | Connor T. A. Brenna Shawn Khan George Djaiani Darren Au Simone Schiavo Mustafa Wahaj Ray Janisse Rita Katznelson |
| author_facet | Connor T. A. Brenna Shawn Khan George Djaiani Darren Au Simone Schiavo Mustafa Wahaj Ray Janisse Rita Katznelson |
| author_sort | Connor T. A. Brenna |
| collection | DOAJ |
| description | Hyperbaric oxygen therapy (HBOT) is known to be associated with pulmonary oxygen toxicity. However, the effect of modern HBOT protocols on pulmonary function is not completely understood. The present study evaluates pulmonary function test changes in patients undergoing serial HBOT. We prospectively collected data on patients undergoing HBOT from 2016–2021 at a tertiary referral center (protocol registration NCT05088772). Patients underwent pulmonary function testing with a bedside spirometer/pneumotachometer prior to HBOT and after every 20 treatments. HBOT was performed using 100% oxygen at a pressure of 2.0–2.4 atmospheres absolute (203–243 kPa) for 90 minutes, five times per week. Patients’ charts were retrospectively reviewed for demographics, comorbidities, medications, HBOT specifications, treatment complications, and spirometry performance. Primary outcomes were defined as change in percent predicted forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and forced mid-expiratory flow (FEF25-75), after 20, 40, and 60 HBOT sessions. Data was analyzed with descriptive statistics and mixed-model linear regression. A total of 86 patients were enrolled with baseline testing, and the analysis included data for 81 patients after 20 treatments, 52 after 40 treatments, and 12 after 60 treatments. There were no significant differences in pulmonary function tests after 20, 40, or 60 HBOT sessions. Similarly, a subgroup analysis stratifying the cohort based on pre-existing respiratory disease, smoking history, and the applied treatment pressure did not identify any significant changes in pulmonary function tests during HBOT. There were no significant longitudinal changes in FEV1, FVC, or FEF25-75 after serial HBOT sessions in patients regardless of pre-existing respiratory disease. Our results suggest that the theoretical risk of pulmonary oxygen toxicity following HBOT is unsubstantiated with modern treatment protocols, and that pulmonary function is preserved even in patients with pre-existing asthma, chronic obstructive lung disease, and interstitial lung disease. |
| first_indexed | 2024-03-13T07:32:14Z |
| format | Article |
| id | doaj.art-286a7e863c724b36b91b2723a284a6c3 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-03-13T07:32:14Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-286a7e863c724b36b91b2723a284a6c32023-06-04T05:31:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01185Pulmonary function following hyperbaric oxygen therapy: A longitudinal observational studyConnor T. A. BrennaShawn KhanGeorge DjaianiDarren AuSimone SchiavoMustafa WahajRay JanisseRita KatznelsonHyperbaric oxygen therapy (HBOT) is known to be associated with pulmonary oxygen toxicity. However, the effect of modern HBOT protocols on pulmonary function is not completely understood. The present study evaluates pulmonary function test changes in patients undergoing serial HBOT. We prospectively collected data on patients undergoing HBOT from 2016–2021 at a tertiary referral center (protocol registration NCT05088772). Patients underwent pulmonary function testing with a bedside spirometer/pneumotachometer prior to HBOT and after every 20 treatments. HBOT was performed using 100% oxygen at a pressure of 2.0–2.4 atmospheres absolute (203–243 kPa) for 90 minutes, five times per week. Patients’ charts were retrospectively reviewed for demographics, comorbidities, medications, HBOT specifications, treatment complications, and spirometry performance. Primary outcomes were defined as change in percent predicted forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and forced mid-expiratory flow (FEF25-75), after 20, 40, and 60 HBOT sessions. Data was analyzed with descriptive statistics and mixed-model linear regression. A total of 86 patients were enrolled with baseline testing, and the analysis included data for 81 patients after 20 treatments, 52 after 40 treatments, and 12 after 60 treatments. There were no significant differences in pulmonary function tests after 20, 40, or 60 HBOT sessions. Similarly, a subgroup analysis stratifying the cohort based on pre-existing respiratory disease, smoking history, and the applied treatment pressure did not identify any significant changes in pulmonary function tests during HBOT. There were no significant longitudinal changes in FEV1, FVC, or FEF25-75 after serial HBOT sessions in patients regardless of pre-existing respiratory disease. Our results suggest that the theoretical risk of pulmonary oxygen toxicity following HBOT is unsubstantiated with modern treatment protocols, and that pulmonary function is preserved even in patients with pre-existing asthma, chronic obstructive lung disease, and interstitial lung disease.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231819/?tool=EBI |
| spellingShingle | Connor T. A. Brenna Shawn Khan George Djaiani Darren Au Simone Schiavo Mustafa Wahaj Ray Janisse Rita Katznelson Pulmonary function following hyperbaric oxygen therapy: A longitudinal observational study PLoS ONE |
| title | Pulmonary function following hyperbaric oxygen therapy: A longitudinal observational study |
| title_full | Pulmonary function following hyperbaric oxygen therapy: A longitudinal observational study |
| title_fullStr | Pulmonary function following hyperbaric oxygen therapy: A longitudinal observational study |
| title_full_unstemmed | Pulmonary function following hyperbaric oxygen therapy: A longitudinal observational study |
| title_short | Pulmonary function following hyperbaric oxygen therapy: A longitudinal observational study |
| title_sort | pulmonary function following hyperbaric oxygen therapy a longitudinal observational study |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231819/?tool=EBI |
| work_keys_str_mv | AT connortabrenna pulmonaryfunctionfollowinghyperbaricoxygentherapyalongitudinalobservationalstudy AT shawnkhan pulmonaryfunctionfollowinghyperbaricoxygentherapyalongitudinalobservationalstudy AT georgedjaiani pulmonaryfunctionfollowinghyperbaricoxygentherapyalongitudinalobservationalstudy AT darrenau pulmonaryfunctionfollowinghyperbaricoxygentherapyalongitudinalobservationalstudy AT simoneschiavo pulmonaryfunctionfollowinghyperbaricoxygentherapyalongitudinalobservationalstudy AT mustafawahaj pulmonaryfunctionfollowinghyperbaricoxygentherapyalongitudinalobservationalstudy AT rayjanisse pulmonaryfunctionfollowinghyperbaricoxygentherapyalongitudinalobservationalstudy AT ritakatznelson pulmonaryfunctionfollowinghyperbaricoxygentherapyalongitudinalobservationalstudy |